Phase 2 N=29 Naltrexone and Hypoglycemia in Type 1 Diabetes
Type 1 Diabetes · Hypoglycemia Unawareness
Primary: Cerebral Blood Flow — 1.7; 1.3 percentage of signal intensity change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=35 Insulin Sensitivity, Impaired Counterregulation, and Glucose Variability
Type 1 Diabetes Mellitus
Primary: Insulin Sensitivity — 3.37*10^-4 1/min per uU/mL
N/A N=27 Effects of Mild Hypoglycaemia on Cognitive Function in Type 2 Diabetes
Diabetes Mellitus, Type II · Hypoglycemia · Cognitive Change
Primary: Psychomotor Speed — 48.7; 56.6 score on a scale
N/A N=16 Cognition in Patients With Hypoglycemia, Without Diabetes
Hypoglycemia · Cognition
Primary: Assessment of Immediate Verbal Memory — 50; 48 RAVLT scores on a scale (range 0 to 69) — p=0.90
Early Phase 1 N=20 Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 4
Type 2 Diabetes
Primary: Percent Changes in Endothelial Function as Measured by Flow Mediated Dilation by 2D Doppler Ultrasound on Day 2 — 2; 7 percentage of change
N/A N=21 Hypoglycemia and the Mineralocorticoid Receptor
Hypoglycemia
Primary: Change From Baseline in Cardiovascular Autonomic Function — -16.00; -16.59 ms/mmHg
N/A N=17 Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia
Hypoglycemia
Primary: Glucose (mg/dL) — 56.5; 52.8; 55.0; 52.8 mg/dL
N/A N=11 Hypoglycemia (Low Blood Sugar) and the Heart
Hypoglycemia · Type 2 Diabetes
Primary: Number of Participants With Hypoglycemia (Blood Sugar Level <70 mg/dl — 11 Participants
N/A N=30 Biobehavioral Mechanisms of Glucose Variability
Diabetes Mellitus, Type 1
Primary: Change Between Pre and Post Challenge Glucose Variability — 0.51; 1.62; 3.71; 0.97 score on a scale
N/A N=7 Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia
Postprandial Hypoglycemia
Primary: Mean Plasma Glucose Area Under the Curve (AUC 0-3h) — 22,192.5; 25,207.1; 21,715.9 mg*min/dl
N/A N=14 Effect of Formoterol on the Counterregulatory Hormonal Response to Hypoglycemia in Type 1 Diabetes.
Type 1 Diabetes
Primary: Glucagon (pg/mL) — 76; 74; 53; 56 pg/mL
N/A N=50 A Cognitive Behavioral Therapy (CBT) Intervention to Reduce Fear of Hypoglycemia in Type 1 Diabetes
Type 1 Diabetes Mellitus
Primary: Fear of Hypoglycemia — 54.3; 58.7; 35.29; 49.0 units on a scale
N/A N=587 Associated Factors in Perioperative Hypoglycemia in Patients With Diabetes
Diabetes · Hypoglycemia
Primary: Hypoglycemia Incidence — 53; 10 participants — p=<0.001
Phase 2 N=110 GPR119 Agonist for Hypoglycemia in Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: Maximal Glucagon Concentration During Hypoglycemia — 19.9; 22.5; 82.7 pg/mL
N/A N=12 How Common is Hypoglycaemia in Older People With Diabetes Who Fall?
Diabetes · Hypoglycaemia
Primary: Proportion of Participants With Captured Hypoglycaemia — 3 Participants
N/A N=14 Impact of Hypoglycaemia in Patients With Diabetes Mellitus Type 2 on Platelet Activation
Diabetes Mellitus With Hypoglycemia · Diabetes Mellitus, Type 2 · Hypoglycemia
Primary: Changes in Platelet Activation Marker Adenosin Diphosphate (%) — 63; 64.4; 64.4; 61.1 percentage of ADP
N/A N=480 Maternal Lifestyle and Neonatal Hypoglycemia
Hyperinsulinemia · Miscarriages · Pregnancy
Primary: Neonatal Hypoglycemia — 3; 15 neonates
N/A N=6 Testing Glial Pathways to HAAF in Human Subjects Using Carbon 13 Magnetic Resonance Spectroscopy
Diabetes Complications · Hypoglycemia
Primary: Percent Enrichment of Bicarbonate as Measured by Magnetic Resonance Spectroscopy (MRS) — 61.9 % enrichment — p=0.0053
N/A N=21 Detecting Neonatal Hypoglycemia Using Real-Time Continuous Glucose Monitoring (CGM)
Neonatal Hypoglycemia
Primary: Sensor-detected Hypoglycemia — 5; 1 events
N/A N=16 Dipeptidyl Peptidase-4 Inhibitors and Alpha-cell Recovery
Type 1 Diabetes · Hypoglycemia
Primary: Glucagon Response to Acute Hypoglycaemia — 1.33; 1.0; 1.33 pmol/L — p=1.0
Phase 2 N=20 Mini-Dose Glucagon to Treat Non-Severe Hypoglycemia
Diabetes Mellitus, Type 1
Primary: Number of Hypoglycemic Events ≥50 mg/dl 15 Minutes AND ≥ 70 mg/dl 30 Minutes After Initial Treatment — 58; 53 Hypoglycemic Events — p=0.99
Phase 2 N=16 Closed-Loop Glucagon Pump for Treatment of Post-Bariatric Hypoglycemia
Post-bariatric Hypoglycemia
Primary: Number of Participants With Meal-provoked Hypoglycemia, Defined as Sensor Glucose <65 mg/dL — 1; 5 participants — p=0.103
N/A N=10 A Cognitive Behavioral Intervention to Reduce Fear of Hypoglycemia in Young Adults With Type 1 Diabetes
Type1diabetes
Primary: Hypoglycemia Fear Scale Score (HFS_2) — 21.4; 38.6 units on a scale
N/A N=22 Hypoglycemia and Autonomic Nervous System Function
Hypoglycemia
Primary: Change in Baroreflex Sensitivity — 2.3; -1.6 ms/mmHg
N/A N=56 Effect of Dietary Glycemic Index on Beta-cell Function
Impaired Glucose Tolerance · Oxidative Stress · Prediabetes
Primary: Disposition Index — 708; 793; 791 unitless
N/A N=11 Hypoglycemia Prevention After Exercise in Adolescent T1DM Patients Using a Control to Range System
Type 1 Diabetes Mellitus
Primary: Hypoglycemic Events — 0.27; 1.0; 0.18; 0.18 events/patient
N/A N=1,069 The OBSTACLE Hypoglycemia Study (MK-0000-158)
Type 2 Diabetes
Primary: Correlation Between HbA1c Values at Week 12 and Hypoglycemia Scores — -0.1215 Correlation coefficient — p=0.0002
N/A N=22 Closed-Loop Glucagon Administration For Hypoglycemia Treatment
Type 1 Diabetes
Primary: Continuous Glucose Monitor (CGM) Glucose Total Area Over the Curve and Less Than 60 mg/dl — 1015; 4375.68 mg/dl/min
N/A N=41 Counter-Regulatory Impairment and the Effect of Microvascular Insulin Transfer in Type 1 Diabetes Mellitus
Diabetes Mellitus, Type 1
Primary: Maximum Epinephrine Response (LBGI Groups) — 495; 217 pg/ml
N/A N=10 Post Bariatric Closed Loop Glucagon Trial
Hypoglycemia
Primary: Area Over the Curve and <60 mg/dl (CGM) Measured in mg/dl *Min — 1066.30; 2004.80 mg/dl *minute